Preventive Vaccine Market Size, Growth, Global Trends, Forecast 2034

Preventive Vaccine Industry Perspective:

The global preventive vaccine market size was worth around USD 59.83 billion in 2024 and is predicted to grow to around USD 136.46 billion by 2034, with a compound annual growth rate (CAGR) of roughly 9.12% between 2025 and 2034.

Request Free Sample

Key Insights:

• As per the analysis shared by our research analyst, the global preventive vaccine market is estimated to grow annually at a CAGR of around 9.12% over the forecast period (2025-2034)
• In terms of revenue, the global preventive vaccine market size was valued at around USD 59.83 billion in 2024 and is projected to reach USD 136.46 billion by 2034.
• The preventive vaccine market is projected to grow at a significant rate due to the rising public health awareness worldwide.
• Based on the vaccine type, the inactivated vaccines segment is growing at a high rate and will continue to dominate the global market, as per industry projections
• Based on the disease type, the poliovirus segment is anticipated to command the largest market share
• Based on region, North America is projected to dominate the global market during the forecast period

Preventive Vaccine Market: Overview

Preventive vaccines are designed to prevent the user from getting infected with a specific infectious disease. Preventive vaccines are generally used to boost the immune system against viral or bacterial infections. Preventive vaccines do not treat an existing condition but are a precautionary measure against diseases such as polio, mumps, influenza, COVID-19, tetanus, and others. During the forecast period, demand for preventive vaccines is expected to continue growing. The rising health awareness among the general population, the expansion of the healthcare industry, favorable government initiatives, and increased research & development of novel vaccines will emerge as critical market growth drivers in the future.

On the other hand, preventive vaccines for certain types of cancer are gaining fast growth momentum worldwide, offering expansion opportunities for industry players. However, the industry is anticipated to face growth restrictions due to the high cost of development and regulatory hurdles. On the other hand, growing cases of counterfeit vaccines in multiple parts of the world have raised concerns among regulatory authorities.

Preventive Vaccine Market Dynamics

Growth Drivers

How will improved public awareness assist preventive vaccine market growth?

The global preventive vaccine market is expected to benefit from the rising public health awareness worldwide. The general population is gaining more knowledge on the importance of timely preventive vaccines, not only for infants and children but also for adults. For instance, polio vaccines must be provided to children in 4 doses between the ages of 2 months, 4 months, 6 to 18 months, and 4 to 6 years. Government support has played a crucial role in improving public awareness of preventive vaccines and where they can be obtained.

In October 2025, government officials and representatives of health ministries from South Sudan, Somalia, Djibouti, and Yemen conducted a virtual meeting. The officials discussed ways to strengthen efforts in the regions to prevent poliovirus transmission in the African regions. In addition, public health awareness has improved due to access to information through social media channels and the internet. These factors will help fuel demand for preventive vaccines in the coming years.

Growing cases of infectious diseases worldwide are expected to propel market expansion trends in the future

Preventive vaccines are highly effective in preventing transmission of common and rare infectious diseases. In recent times, especially since 2020, the rate of transmission of infectious diseases has skyrocketed. For instance, millions of people contracted COVID-19 in 2020 and 2021. The infection led to several deaths across the globe. Apart from COVID-19, several other types of infectious conditions continue to impact the health of the global population. Some conditions are treatable, while others can be fatal if not treated on time.

In February 2025, the World Health Organization, Uganda’s Ministry of Health, and other partners announced the launch of the first-ever clinical efficacy trial of a preventive vaccine for the Ebola virus from the Sudan species. As the rate of infectious disease transmission continues to grow, the global preventive vaccine market players can expect improved revenue during the forecast period.

Restraints

How will cost-related barriers restrict preventive vaccine market growth?

The global preventive vaccine industry is expected to be limited by the high cost of research & development (R&D) associated with the market. Vaccine development is a long and resource-intensive process. It can take decades to bring a preventive vaccine to market after extensive research & innovation and clinical trials. For instance, the average cost of vaccine development can range between USD 250 million and USD 1.1 billion.

Opportunities

Surging demand for cancer-preventing vaccines offers growth opportunities to the market players

The global preventive vaccine market leaders are investing heavily in developing vaccines that can prevent some forms of cancer. At present, preventive vaccines available in the market are effective in preventing only specific types of cancer-causing infections. The two major preventive cancer vaccines are the Human Papillomavirus vaccine and the Hepatitis B vaccine. The former delivers protection against HPV viruses that can cause vaginal & vulvar cancer, anal cancer, and cervical cancer. The hepatitis B vaccine is effective against hepatitis B viral infections that can cause liver cancer and cirrhosis. Preventive cancer vaccines offer tremendous growth possibilities to the market players.

Why are travel vaccinations registering increased demand in the preventive vaccine industry?

Travel vaccines are recommended preventive vaccines for adults traveling to specific geographical locations. According to regulatory guidelines in some countries, people entering or exiting the region must provide proof of preventive vaccination, especially for diseases such as Hepatitis B, diphtheria, and Hemophilus influenzae type B. Travel vaccinations aim to prevent travelers and the local community from infectious diseases.

Challenges

Regulatory hurdles and scaling complexities to challenge market growth trends

The global preventive vaccine industry is likely to face challenges due to the complexity of regulatory requirements for the development of new vaccines. Additionally, entry for existing vaccines in new markets is delayed by the dynamic regulatory safety protocols and standards. In addition, market players face challenges scaling vaccine production due to insufficient infrastructure, manufacturing capabilities, or funds.

Request Free Sample

Preventive Vaccine Market: Report Scope

Preventive Vaccine Market: Segmentation

The global preventive vaccine market is segmented based on vaccine type, disease type, and region.

Based on vaccine type, the global market is segmented into inactivated vaccines, live/attenuated vaccines, toxoid vaccines, subunit vaccines, and others. In 2024, around 36% of the global market share was held by the inactivated vaccines segment. The rising prevalence of infectious diseases worldwide has fueled demand for inactivated vaccines. These preventive healthcare tools assist in protecting against common diseases such as Hepatitis A, polio, and rabies.

Based on disease type, the global industry is fragmented into Hepatitis, poliovirus, pneumococcal, rubella, measles, and others. In 2024, the poliovirus segment accounted for nearly 56% of the total revenue. The segmental demand is a result of higher government initiatives undertaken worldwide to prevent polio virus transmission. African and Asian countries have a higher demand for preventive vaccines against poliovirus.

Preventive Vaccine Market: Regional Analysis

Which factors contribute to North America’s dominance in the preventive vaccine market?

The global preventive vaccine market will be led by North America during the forecast period. In 2024, the region accounted for nearly 46% of global revenue, with the US holding the highest market share in the regional industry. Growth in North America is led by higher public health awareness and a robust healthcare infrastructure. Medical care architecture in North America generally focuses on providing extensive preventive care against infectious diseases. The US has reported lower statistics for several years in terms of infectious disease transmission in the country.

Furthermore, the presence of prominent regional players further helps the region thrive. Asia-Pacific is a growing market and is expected to emerge as the fastest-growing industry during the forecast period. The rising prevalence of infectious diseases in the country and the growing healthcare expenditure are fueling the regional growth rate.

In September 2025, China announced the launch of domestically developed cervical cancer prevention vaccines for the general population. In addition, players in the Asia-Pacific region have access to a robust manufacturing sector, enabling them to scale vaccine production as global demand increases.

Preventive Vaccine Market: Competitive Analysis

The global preventive vaccine market is led by players like:

• Johnson & Johnson
• GlaxoSmithKline (GSK)
• Pfizer
• Bharat Biotech
• CSL (Seqirus)
• AstraZeneca
• Sinopharm
• Moderna
• Novavax
• Valneva
• Merck
• Serum Institute of India
• Takeda
• Sanofi
• Sinovac

Preventive Vaccine Market: Key Market Trends

Expansion into emerging markets:

Market players are actively investing in expanding business operations in emerging markets. They are seeking opportunities to strategically collaborate with regional stakeholders to develop an improved vaccine supply chain in previously untapped locations.

Advancements in delivery mechanisms:

Investments are being directed toward developing novel delivery mechanisms for preventive vaccines. These new delivery systems include solutions such as needless delivery for better efficacy and to reduce logistical burden.

The global preventive vaccine market is segmented as follows:

By Vaccine Type

• Inactivated Vaccines
• Live/Attenuated Vaccines
• Toxoid Vaccines
• Subunit Vaccines
• Others

By Disease Type

• Hepatitis
• Poliovirus
• Pneumococcal
• Rubella
• Measles
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa